Background. Several studies have demonstrated a shortterm antiproteinuric effect of mineralocorticoid receptor blockers (MRB) on proteinuric kidney diseases, but no information is available about the long-term persistence (>1 year) of such reduction in proteinuria and the longterm effects of MRB on renal function. Methods. We prospectively studied the effects of adding spironolactone (25 mg/day) to 87 patients who maintained proteinuria higher than 1 g/day in spite of renin-angiotensin system blockade. The mean follow-up was 25 ± 15 (1-84) months. Results. Estimated glomerular filtration rate (eGFR) showed an acute fall in the first month of treatment (5.1 ± 9.4 mL/min/1.73 m 2 ), but it remained stable thereafter (+0.04 ± 0.7 mL/min/1.73 m 2 /month), with a significant difference with respect to the eGFR slope during the 12-month pre-treatment period. The initial eGFR fall predicted a more stable course of renal function, the higher the eGFR initial fall, the better the long-term evolution of eGFR. Proteinuria showed an important and sustained reduction since the first month of treatment. At the end of follow-up, it had decreased by 61% (43-77%) with respect to baseline values. The antiproteinuric and renoprotective influence of spironolactone was also observed in diabetic patients and in patients with renal function impairment, although tolerance was poorer among the latter. Conclusions. Spironolactone induces an initial acute fall in eGFR that predicts a later favourable influence on the course of renal function and a remarkable and sustained reduction in proteinuria.
Introduction
The role of aldosterone in the progression of renal failure has been demonstrated in many experimental studies [1] [2] [3] . In the last years, several clinical studies have shown that the use of mineralocorticoid receptor blockers (MRB) (spironolactone, eplerenone) induces a significant proteinuria reduction in patients with many types of proteinuric kidney diseases [4, 5] . Recent prospective randomized controlled trials (RCTs) have demonstrated that MRB, when added to angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in patients with residual proteinuria, reduce proteinuria by 30-55% of baseline values [6] [7] [8] [9] [10] [11] [12] [13] [14] . Nevertheless, the duration of these studies has been very short; only three of them [6] [7] [8] have extended their follow-up to 12 months. Therefore, whether or not the antiproteinuric efficacy of MRB persists beyond the first year of treatment is presently unknown.
Short-term studies with MRB have shown an initial decrease in glomerular filtration rate (GFR) [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , which has been attributed to a transient volume depletion due to the diuretic effect of MRB and to the disappearance of glomerular hyperfiltration. ACEI and ARB also induce a transient initial decrease in GFR and, in fact, it has been shown that this initial decline significantly predicts a more stable course of renal function during long-term follow-up [15, 16] .
In 2004, we started a therapeutic protocol based on the addition of spironolactone to those patients who maintained proteinuria higher than 1 g/day in spite of treatment with ACEI or ARB. In the present study, we aimed, first, to ascertain whether spironolactone treatment decreases the progression of renal failure during long-term followup, second, to examine if the initial decline in GFR induced by spironolactone predicts the outcome of renal function on the long term, third, to analyse whether the antiproteinuric effect of MRB persists beyond the first year of therapy or abates with time and, fourth, to ascertain if the response to MRB in diabetics and in patients with renal insufficiency [(estimated GFR (eGFR) <60 mL/min/1.73 m 2 )] was different from that of patients with normal renal function and renal diseases other than diabetic nephropathy.
Materials and methods

Patients
In January 2004, we began a single-centre prospective cohort study based on the addition of spironolactone to adult patients who maintained proteinuria persistently higher than 1 g/24 h, in spite of maximally tolerated doses of ACEI, ARB or both by more than 6 months and regardless of the aetiology of kidney disease. There were no limitations based on age or kidney function. We excluded patients with serum potassium >6 mEq/L during ACEI/ARB therapy, nephrotic syndrome ( proteinuria >3.5 g/day and serum albumin <3 g/dL), acute or subacute decrease of kidney function, weakening conditions or immunosuppressive therapy for glomerular or systemic diseases.
Eighty-seven patients were included in this protocol. This trial was approved by the Ethical Committee of the Hospital.
Therapeutic intervention
Spironolactone, at a dose of 25 mg/day, was added to baseline treatment in all cases. At the follow-up, the dose of spironolactone was modified according to blood pressure (BP) or serum potassium levels, and in some patients with insufficient antiproteinuric response (<30% of baseline values) but a good tolerance, the dose was increased to 50 mg/day.
In patients with a poor tolerance to the drug different from hyperkalaemia (mainly gynaecomastia), spironolactone was replaced by eplerenone, at a dose of 25 mg/day. Baseline doses of ACEI, ARB or both were not changed at the beginning of study. Subsequently, they were modified in some patients according to BP and serum potassium levels. In some patients with an antiproteinuric response >30% of baseline values but a difficult control of serum potassium, ACEI/ARB were progressively reduced and, in some cases, discontinued. For an adequate control of serum potassium, we advised a low potassium diet to all patients. When insufficient, cation-exchange resins, thiazide agents and MRB dose reduction were prescribed. A target of BP < 130/80 mmHg was established. Other antihypertensive agents, in addition to ACEI, ARB and MRB, were prescribed in some patients to obtain BP target.
Follow-up and data collection
All patients were seen at an outpatient clinic after 1 month of spironolactone treatment. Thereafter, patients were checked every 2 months during the firsts 6 months, every 3 months during the next 6 months and every 4-6 months after the first year of treatment. The mean follow-up was 25 ± 15 (1-84) months.
Outcome
The main outcome of the study was the change of the mean eGFR from the first month of spironolactone treatment to the end of follow-up. This change was compared with eGFR changes during the 12-month period previous to the treatment. Secondary outcomes were the impact of initial eGFR decline (at 1 month) on the course of renal function during follow-up, the reduction in proteinuria after MRB introduction, its persistence during long-term follow-up and the number of patients achieving a proteinuria reduction >50% of baseline values. The response to MRB treatment of diabetic patients and patients with eGFR < 60 mL/ min/1.73 m 2 at baseline were separately analysed. Tolerance to spironolactone and side effects were also analysed.
Definitions
The follow-up period was calculated as the interval between the beginning of spironolactone treatment and the last visit, discontinuation of MRB treatment, end-stage renal disease (ESRD) (eGFR <15 mL/min/ 1.73 m 2 ) or death. Renal function was measured by eGFR using the modification of diet in renal disease (MDRD) formula. Mean arterial pressure (MAP) was calculated as the sum of diastolic BP plus one-third of the difference between systolic and diastolic BPs.
Statistical analysis
We calculated changes in eGFR and 24-h proteinuria decline in three different periods: during the 12-month period previous to the start of spironolactone treatment, during the first month after the onset of spironolactone treatment (+1 month) and during the long-term follow-up beyond the first month of treatment (+3, +6, +12 months and at the end of the follow-up). We compared changes of these parameters between Months 0 and 1 (defined as delta 1) versus changes between Months 1-6 (delta 2), Months 1-12 (delta 3) and Month 1 and the end of the followup (delta 4). In order to estimate the impact of initial eGFR decline on the long-term outcome of renal function, patients were divided into subgroups (tertiles) of acute fall in eGFR during the first month of MRB treatment.
Data are expressed as the mean ± SEM, or the median and inter-quartile range for normal and non-normal continuous variables, respectively. Spearman's ranks correlation, paired t-tests and the Wilcoxon test were performed when indicated. Qualitative variables were compared by means of the χ 2 test. Binomial logistic regression was used to determine the impact of relevant baseline characteristics on final kidney function. For this purpose, we defined the outcome of kidney function as a dichotomic variable in relation to its increase or not, at the end of the follow-up: positive, when final eGFR change increased ≥1 mL/min/year with respect to its value at +1 month after spironolactone treatment, and negative, when this change was <1 mL/min/year. First, we performed a univariate analysis with each baseline variable. Then, statistically significant variables in univariate analysis, variables with 0.05 < P < 0.25, and those with biological plausibility to impact on kidney function were introduced in a multivariable model by the backward step method. We explored potential interaction between variables in the model. No statistically significant interactions were excluded from the final model. The model goodness-of-fit was evaluated by the Hosmer-Lemeshow test. We reported adjusted odds ratio and 95% confidence intervals. For all tests, P-values of <0.05 were considered to be statistically significant. Data were evaluated using SPSS version 15.0 for Windows (SPSS, Chicago, IL).
Results
Patient characteristics
Eighty-seven patients were included in the therapeutic protocol with spironolactone. Their demographic, clinical and analytical characteristics at baseline are shown in Table 1 .
The number of patients who were treated with antihypertensive drugs other than ACEI, ARB or MRB at baseline and at the end of follow-up was as follows: calcium channels blockers, 10 (11%) and 8 (9%), respectively; β-blockers 7 (8%) and 7 (8%); α-blockers 6 (7%) and 5 (4%) and diuretics 16 (18%) and 24 (27%). After the onset of MRB treatment, ACEI were tapered and finally discontinued in 15 patients, and the same occurred for ARB in 20 patients. The number of patients treated with Table 1 ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; eGFR, estimated glomerular filtration rate; F, female; M, male; MAP, mean arterial pressure; SCr, serum creatinine.
the combination ACEI+ARB decreased from 21 at baseline to only 3 at the end of follow-up. Forty-seven patients were treated with ARB+MRB, 20 with ACEI+MRB and 3 with ACEI+ARB+MRB at the end of follow-up, whereas 17 patients were receiving an MRB alone.
Long-term evolution of renal function
As shown in Table 2 and Figure 1 , kidney function had significantly deteriorated during the −12-month period before spironolactone treatment (−0.35 ± 1.1 mL/min/ 1.73 m 2 /month). After the first month of spironolactone treatment, renal function showed a significant fall (5.1 ± 9.4 mL/min/1.73 m 2 with respect to baseline). An eGFR increase was observed from the first month of treatment to the end of follow-up (+0.04 ± 0.76 mL/min/1.73 m 2 /month), with a significant difference between the slope of eGFR during the −12-month period and the slope of eGFR beyond the first month of treatment (P = 0.028). Forty-nine patients (56%) showed an improvement of kidney function during long-term follow-up.
As shown in Figure 2 and Table 3 , there was a significant association between the initial decline in eGFR after spironolactone and the long-term renal function outcome. When dividing the patients into tertiles according to the initial acute fall in eGFR, those with a greater decline showed a more favourable course of renal function on the long term, in contrast with patients with lower eGFR initial fall. No significant associations between initial eGFR decline and eGFR changes at months +3 and +6 were observed.
Multivariate analysis, as shown in Table 3 , indicated that eGFR initial decline after spironolactone treatment, both analysed as a continuous variable (absolute change between baseline and +1 month) and as a categorical variable (higher tertile of eGFR initial decline, model 2), was the only independent and significant factor predicting a more stable course of renal function during follow-up.
To better investigate if the initial eGFR decline was due to hyperfiltration disappearance or to progression of the disease, we analysed eGFR changes in a subgroup of 23 patients with stable renal function before treatment (eGFR changes between −2 and +2 mL/min during the 12-month period before treatment). Their mean eGFR at −12 month before treatment was 56.3 ± 33.3 mL/min/1.73 m 2 and it was very similar at baseline (56 ± 33.4 mL/min/1.73 m 2 ). One month after the onset of MRB treatment, eGFR had significantly fallen to 52.6 ± 31.5 mL/min/1.73 m 2 , but it remained stable thereafter (eGFR at +12 month, 52.1 ± 31.5 mL/min/1.73 m 2 ).
Proteinuria
We observed an important decline of proteinuria from the first month of spironolactone treatment (from 3 ± 2 to 1.8 ± 1.4 g/day, P < 0.05, representing a 42% decrease from baseline values). The mean reduction of proteinuria increased above 47% at 6 months, and to more than 63% at 12 months, without tendency to decline during the follow-up (Tables 2 and 4 , Figures 3 and 4) . At the end of the follow-up, proteinuria was 1.1 ± 1.2 g/day (P < 0.0001 versus baseline), representing a reduction of 63% (range 44-77%) versus baseline value. As shown in Figure 4 , a majority of patients achieved proteinuria reductions higher than 50% of baseline values and this remarkable reduction persisted throughout follow-up. No correlation was found between eGFR and proteinuria changes (r = 0.067, P = 0.537). A non-significant trend towards greater stabilization of kidney function was observed in patients with higher reductions of proteinuria (r = 0.202, P = 0.08).
BP and serum potassium changes BP significantly decreased during the first month of spironolactone treatment (Tables 2 and 4 ) and it remained stable beyond. Serum potassium significantly increased after the first month of treatment, but it remained stable during follow-up (Tables 2 and 4) . No significant influence of BP changes on eGFR outcome was found.
Diabetic patients and patients with decreased eGFR at baseline
As shown in Table 2 and Figure 4 , eGFR and proteinuria changes in diabetic patients mirrored that of non-diabetic ones: an eGFR decrease during the first month of treatment, followed by a stabilization of renal function thereafter and a significant and sustained reduction in proteinuria. Regarding those patients with eGFR lower than 60 mL/min/1.73 m 2 at baseline, a reduction in proteinuria was also remarkable, although eGFR changes were less pronounced than in patients with baseline eGFR >60 mL/ min/1.73 m 2 ( Table 2 , Figures 1 and 4 ).
Baseline treatment with ACEI, ARB or ACEI+ARB
As shown in Table 4 , eGFR and proteinuria changes were similar in those patients receiving monotherapy with ACEI or ARB, or dual blockade ACEI+ARB at baseline. Likewise, no significant differences were found regarding changes in BP and serum potassium.
Safety and tolerance of spironolactone treatment
No patient died nor developed ESRD or doubling of baseline serum creatinine. Fourteen patients (16%) developed gynaecomastia shortly after the onset of spironolactone treatment and were switched to eplerenone (25 mg/day). There were no differences regarding renal function and proteinuria outcomes between patients switched to eplerenone and those who remained on spironolactone. During the study, 14 patients (16%) discontinued the treatment with MRB (13 spironolactone, 1 eplerenone) due to persistent hyperkalaemia (>5.5-6 mEq/L) in spite of therapeutic measures in 10 patients, and clinically relevant acute decrease in renal function (>30% increase in baseline serum creatinine values) in 3. The remaining patient had a possible allergic reaction to spironolactone and refused substitution by eplerenone. In these 14 patients, MRB were definitively withdrawn, without switching to another MRB. All patients except one (12/13) who discontinued MRB due to hyperkalaemia or acute renal function decrease had an eGFR < 60 mL/min/1.73 m 2 at baseline. MRB discontinuation occurred between 1 and Table 2 . Evolution of the main clinical and analytical factors before and after treatment with MRB in all the patients (n = 87), diabetic patients (n = 42) and patients with eGFR at baseline <60 mL/min/1.73 m 19 months after the onset of treatment (mean 9 ± 5 months). No patient treated with ACEI at baseline (n = 19) discontinued MRB, whereas MRB were withdrawn in 11 (22%) out of 49 patients receiving ARB at baseline (hyperkalaemia in 9, acute renal function impairment in 2) and in 3 (14%) out of 21 patients on ACEI +ARB combined treatment at baseline (1 hyperkalaemia, 1 acute renal function impairment, 1 allergic reaction). At the end of the follow-up, 56 patients were receiving concomitant treatment for hyperkalaemia (36 cationsexchange resins, 24 low doses of thiazides) and mean doses of spironolactone and eplerenone were 27.2 ± 14.1 mg/24 h (12.5-100) and 37.5 ± 17.7 mg/24 h (12.5-75), respectively. 
Discussion
Our study provides clinical information about the longterm course of renal function in a cohort of patients with different types of kidney diseases who were treated with spironolactone because of the persistence of proteinuria > 1 g/day in spite of treatment with ACEI or ARB. As shown in Table 2 and Figure 1 , renal function showed a progressive decline in the 12-month period before spironolactone treatment. An acute fall in eGFR (5.4 ± 9.9 mL/min/1.73 m 2 ) Table 4 . Evolution of the main clinical and analytical factors before and after treatment with MRB in patients with ACEI (n = 17), ARB (n = 49) and ACEI+ARB (n = 21) at baseline was observed during the first month of treatment. However, renal function tended to improve beyond the first month of treatment and the comparison of eGFR slopes during the −12 month pre-treatment period and +1 month long-term follow-up showed a significant difference. A similar trend of renal function after spironolactone treatment was observed in two studies that analysed the effect of MRB for 1 year [6, 7] . The longer follow-up of our study allows us to confirm this clinically important beneficial influence of spironolactone on renal function. Interestingly, we found a significantly inverse correlation between the magnitude of MRB-induced initial fall in eGFR and the long-term outcome of renal function, as shown in Figure 2 . To exclude that the initial decline in eGFR was not due to the progression of the disease, we analysed separately those patients with a more stable course before MRB treatment, obtaining a profile of eGFR changes very similar to that of the remaining patients. A similar predictive significance of initial acute fall in GFR had been reported with ACEI [15] , and it has been confirmed at a larger scale in a recent post-analysis of RENAAL trial among patients treated with losartan [16] . Accordingly, a post hoc analysis of patients treated with eplerenone in the EPHESUS trial has shown an acute initial fall in eGFR followed by long-term eGFR stabilization [17] . MRB have been shown to counteract glomerular hyperfiltration in experimental models of chronic renal failure [18] [19] [20] .
In addition to these haemodynamic changes, there are multiple ways through which MRB can induce a beneficial effect on the progression of chronic renal diseases (reviewed in Pitt et al. [21] ). On the other hand, some RCTs have demonstrated a cardioprotective influence of MRB on patients with heart failure [21, 22] .
Our study shows that the remarkable short-term antiproteinuric effect of MRB, as reported in previous studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] persists without changes during longer follow-up. The antiproteinuric effect was remarkably homogeneous, most patients showing sustained proteinuria reductions higher than 50%. A non-significant trend towards greater stabilization of kidney function was observed in patients with higher reductions of proteinuria (r = 0.202, P = 0.08).
Our data also provide clinically important information about the benefits and safety of MRB treatment in diabetic patients and in patients with reduced renal function at baseline. As shown in Table 2 and Figure 4 , the response to spironolactone in these subgroups was similar to that of the whole group of patients. However, it is important to stress that MRB-induced serious complications (hyperkalaemia in 10 patients, severe acute decline in renal function in 3) were almost exclusively observed among patients with reduced renal function at baseline (eGFR < 60 mL/min/1.73 m 2 ). On the contrary, spironolactone was very well tolerated in patients with better renal function at baseline. Although serum potassium showed a significant increase after the onset of spironolactone, it was easily controlled with low-potassium diets, cations-exchange resins or low doses of thiazide diuretics. Gynaecomastia was a common minor side effect of spironolactone, observed in 11% of patients, and it was completely resolved by switching to eplerenone, another MRB that does not share this complication.
Although our results show a low incidence of hyperkalaemia and other serious complications, it is important to stress that a careful monitoring was regularly performed in our patients and that this policy should be strongly recommended in all the patients treated with MRB, particularly in those cases with even mild degrees of renal impairment. A majority of patients (56 out of 87) were receiving concomitant treatment for hyperkalaemia (36 cations-exchange resins, 24 low doses of thiazides) at the end of follow-up. Therefore, hyperkalaemia should be continuously monitored and appropriate treatment started if it appears.
Recent studies have alerted about the risk of serious complications (renal function impairment, hyperkalaemia and hypotension), among patients treated with dual-blockade ACEI+ARB [23] . We did not observe more side effects after introducing MRB in patients receiving ACEI +ARB when compared with those treated with either ACEI or ARB alone. However, the majority of patients treated with dual blockade at baseline (18 out of 21) discontinued either ACEI or ARB during the follow-up, owing to a better BP control and a satisfactory proteinuria reduction after MRB introduction. In this regard, our data suggest that ACEI+MRB or ARB+MRB combination could be an interesting alternative to dual blockade ACEI +ARB. However, the lack of a control group is an important limitation of our study and RCTs are needed to demonstrate the renoprotective role of MRB in proteinuric chronic kidney diseases.
Further comparative studies are required to determine whether or not these antiproteinuric and renoprotective effects of MRB are shared by other types of diuretics, since some studies have shown that thiazides can induce significant reductions in proteinuria when added to ACEI/ ARB treatment [24, 25] . Likewise, sodium restriction potentiates the antiproteinuric response to ACEI/ARB [24, 26] and the combination of hydrochlorothiazide with low-sodium diet further augments the response [24] .
In summary, MRB treatment in patients with different types of proteinuric kidney diseases induces a significant slowing in the progression of renal failure, associated with a remarkable and sustained reduction in proteinuria. Tolerance to MRB treatment was reassuring, particularly among patients with normal renal function. However, MRB treatment should be carefully monitored in patients with decreased renal function because of the threat of hyperkalaemia.
